Nature Reviews Cancer Impact Factor

The impact factor tells you that Nature Reviews Cancer articles are cited at an extraordinary rate. But this number requires context: review journals generate fundamentally different citation patterns than primary research journals.

A comprehensive review in Nature Reviews Cancer becomes the default citation for an entire cancer subfield. When researchers write introductions, frame hypotheses, or describe the state of the art, they cite these reviews. That citation behavior is structural and persistent. The five-year JIF of 85 running well above the two-year (60.7) confirms that these reviews keep accumulating citations for years.

The practical implication for most cancer researchers: Nature Reviews Cancer's JIF should not enter your submission planning for primary research manuscripts. It belongs in a different category entirely.

Source: Clarivate Journal Citation Reports historical data, refreshed against the 2026 JCR release in July 2026.

Nature Reviews Cancer is down from 66.8 in the 2024 data year to 60.7 in the 2025 data year, after the 78.5 pandemic-era peak in 2022. The five-year JIF of 85 still confirms extraordinary long-tail citation performance, so the current decline is better read as citation normalization than as a change in the journal's invited-review role.

The category rank tells a different story than the absolute IF and is the metric that matters most for tenure committees and promotion files that weight quartile and rank position rather than raw citation counts.

Source: Clarivate Journal Citation Reports, Oncology category, refreshed against the 2026 JCR release in July 2026.

The category has substantially more journals indexed than in 2014, which reflects the expansion of the cancer-research publishing ecosystem rather than dilution. Nature Reviews Cancer has held a top-5 position throughout this expansion and remains ranked 4 of 333 in the current JCR row. For career evaluation, the rank position is often more durable than the absolute IF, which fluctuates with citation cycles.

Across Manusights submission reviews of Nature Reviews Cancer proposals, three failure patterns generate the most consistent declined proposals. The journal commissions most reviews by direct invitation; unsolicited proposals are accepted but rarely succeed.

Proposals that describe a topic rather than identify a gap. Editors evaluate whether the proposed review would "fill a gap" in the existing literature, their documented framing. The most common failure is pitching "a comprehensive review of [mechanism] in [cancer type]" when that mechanism already has adequate review coverage. Editors track the review landscape and will not commission redundant coverage.

A proposal that succeeds identifies a specific gap: findings have accumulated to the point where the conceptual framework has shifted, but a synthesis has not been written. The proposal should name the specific papers or developments that created the gap and explain why existing reviews no longer adequately cover the area.

Proposals from researchers without deep subfield authority. Nature Reviews Cancer's credibility depends on reviews written by researchers with established primary research records in the exact topic being reviewed. Proposals from researchers who have broad oncology expertise but no specific track record in the proposed area (a colorectal cancer researcher proposing a review of neuroblastoma) will not succeed.

Editors look for multiple high-impact primary research papers in the specific area being reviewed, plus recognition at the field's major meetings. Building the track record in a subfield through primary research publications is the prerequisite; the review invitation typically follows years later.

Proposals with scope too broad for the review format. Nature Reviews Cancer reviews are typically 6,000-8,000 words covering a focused topic with enough depth to be useful to both specialists and non-specialist cancer researchers. Proposals for reviews covering "the tumor microenvironment" or "metabolic reprogramming in cancer" without a specific mechanistic focus or conceptual framing are returned because the scope does not fit the format.

A successful proposal is specific: "the metabolic crosstalk between cancer-associated fibroblasts and tumor cells in hypoxic environments" is reviewable at depth; "cancer metabolism" is not. If you are considering proposing a review, a Nature Reviews Cancer proposal scope and framing check can assess whether the gap identification and scope are positioned appropriately for the editors' decision framework.

Nature Reviews Cancer's JIF is driven by several structural factors:

• Review articles are cited more often than primary research articles as a baseline

• The journal publishes a small number of articles per year (around 60 to 65 citable items), which concentrates the citation density

• Each review covers an entire subfield, making it a citation magnet for anyone working in that area

• The Nature Reviews brand ensures high visibility and discoverability

• Cancer is one of the most heavily published and cited areas in biomedical research

These factors combine to produce a JIF that is structurally higher than any primary research journal in oncology. The number does not mean that an individual review in Nature Reviews Cancer is "better" than an individual paper in Cancer Cell. It means the citation dynamics of comprehensive reviews in a heavily published field produce very high per-article citation rates.

Unlike primary research journals, Nature Reviews Cancer operates primarily on invitation. The editorial process typically works in one of two ways:

1. The editors identify a topic and invite an expert to write the review

1. A researcher proposes a review topic to the editors, who evaluate whether it fills a gap

If you have deep expertise in a cancer subfield and believe a comprehensive review would serve the field, approaching the editors with a well-framed proposal is reasonable. But the journal's editorial team ultimately decides which topics to commission.

For researchers who want to write review articles but are not at the invitation stage, other strong cancer review options exist, including Cancer Discovery, Clinical Cancer Research, and disease-specific review journals.

In our experience reviewing proposals before they go to Nature Reviews editorial offices, the gap identification is where most proposals fail. An editor managing a cancer review journal has read every recent synthesis in the field and tracks what has and hasn't been covered.

A proposal that opens with "cancer remains a leading cause of death worldwide" and then lists the topics the review will cover is describing a subject area, not making a case for a specific gap.

The proposals that get commissioned name the specific tension: conflicting findings about a mechanism, a model that has held for a decade but is now being challenged by single-cell data, a therapeutic area that has seen multiple failed trials whose failure nobody has synthesized into a coherent framework.

If the proposal does not answer "why does this review need to exist right now and not two years ago," it will not succeed.

If you are looking for a primary research target in oncology, the relevant comparison set does not include Nature Reviews Cancer. Instead, consider:

• Cancer Cell JIF 56.1: field-defining cancer biology with Cell Press editorial standards

• Annals of Oncology JIF 80.4: practice-changing clinical oncology

• Lancet Oncology JIF 33.7: clinical oncology with broad reach

• Nature Medicine JIF 52.5: translational research including oncology

For primary cancer research, a cancer research journal fit check can help identify the right target journal based on your manuscript's strengths and the appropriate editorial bar.

• Whether you will be invited to write for the journal

• How to approach the editors with a review proposal

• Whether your primary research belongs in a cancer journal or a broader venue

• The acceptance rate for unsolicited review proposals

• How a review publication compares to primary research for career evaluation

Nature Reviews Cancer's 60.7 is one of the easiest metrics in the queue to misread because it belongs to a review journal, not a standard primary-research venue. The number is elite because the journal publishes broad synthesis pieces that become default citations across oncology. That makes the journal influential, but it also means the metric is describing article type as much as editorial quality.

If you compare it directly with Cancer Cell or other original-research journals, you will overestimate what the JIF can tell you about submission strategy.

The useful decision question is narrower. Nature Reviews Cancer makes sense when the project is genuinely review-shaped: a timely synthesis, a field-resetting framework, or an invited perspective from authors with obvious authority. It is the wrong lens for a primary cancer manuscript, no matter how strong the data are. In that sense, the huge gap between the two-year and five-year numbers is not just a prestige story. It is evidence that these articles stay in the citation bloodstream as field-defining references for years.

Use the trend as a guardrail against the wrong kind of ambition. Nature Reviews Cancer is valuable because it shapes how oncology is interpreted, not because it functions as a benchmark for ordinary submission planning. If the page helps a searcher realize that article type matters more than the headline number, then the page is doing the job this query actually needs.